open access

Vol 68, No 5-6 (2018)
Research paper (original)
Published online: 2019-05-07
Get Citation

The efficacy of radical radiotherapy for patients with primarily diagnosed prostate cancer with metastases to regional lymph nodes

Tomasz Krzysztofiak, Wojciech Majewski
DOI: 10.5603/2018.0040
·
Nowotwory. Journal of Oncology 2018;68(5-6):253-258.

open access

Vol 68, No 5-6 (2018)
Original article
Published online: 2019-05-07

Abstract

Objectives. Retrospective analysis of 22 patients with high risk prostate cancer and clinical regional lymph node involvement treated with radical radiotherapy and ADT. Material and methods. The mean pre-treatment PSA level was 69 ng/ml. Median age — 65 years. Lymph nodes involvement was determined by radiological imaging. Duration of ADT was 2–3 years. All patients underwent conventional radiotherapy. Dose to the prostate ranged from 75.6 to 78 Gy, to elective lymph nodes — 44 to 50 Gy, boost dose to involved lymph nodes — 60 to 75,6 Gy. Median follow-up was 40 months. Results. The 3-year and prognosed 5-year bCR in studied group was 78% and 65%. The 3-years and 5-years prognosed OS was 88% and 73%. We observed 5 failures. No relapse in a nodal boost region was observed. No dose-effect relationship was observed for bCR nor OS. Only T stage proved prognostic for bCR. Conclusions. The results showed good outcome for node positive prostate cancer patients treated with radical intent. No dose-effect relationship suggest that metastatic pelvic lymph nodes may not require such dose escalation as primary tumor.

Abstract

Objectives. Retrospective analysis of 22 patients with high risk prostate cancer and clinical regional lymph node involvement treated with radical radiotherapy and ADT. Material and methods. The mean pre-treatment PSA level was 69 ng/ml. Median age — 65 years. Lymph nodes involvement was determined by radiological imaging. Duration of ADT was 2–3 years. All patients underwent conventional radiotherapy. Dose to the prostate ranged from 75.6 to 78 Gy, to elective lymph nodes — 44 to 50 Gy, boost dose to involved lymph nodes — 60 to 75,6 Gy. Median follow-up was 40 months. Results. The 3-year and prognosed 5-year bCR in studied group was 78% and 65%. The 3-years and 5-years prognosed OS was 88% and 73%. We observed 5 failures. No relapse in a nodal boost region was observed. No dose-effect relationship was observed for bCR nor OS. Only T stage proved prognostic for bCR. Conclusions. The results showed good outcome for node positive prostate cancer patients treated with radical intent. No dose-effect relationship suggest that metastatic pelvic lymph nodes may not require such dose escalation as primary tumor.

Get Citation

Keywords

radiotherapy; prostate cancer; oncology

About this article
Title

The efficacy of radical radiotherapy for patients with primarily diagnosed prostate cancer with metastases to regional lymph nodes

Journal

Nowotwory. Journal of Oncology

Issue

Vol 68, No 5-6 (2018)

Article type

Research paper (original)

Pages

253-258

Published online

2019-05-07

Page views

363

Article views/downloads

908

DOI

10.5603/2018.0040

Bibliographic record

Nowotwory. Journal of Oncology 2018;68(5-6):253-258.

Keywords

radiotherapy
prostate cancer
oncology

Authors

Tomasz Krzysztofiak
Wojciech Majewski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl